Zhejiang Ausun Pharmaceutical Co.,Ltd. (603229.SH) disclosed its 2025 semi-annual report. During the reporting period, the company achieved revenue of 482 million yuan, representing a year-over-year decline of 2.14%; net profit attributable to shareholders reached 169 million yuan, down 5.83% year-over-year; non-recurring items adjusted net profit totaled 151 million yuan, decreasing 12.29% year-over-year; basic earnings per share stood at 0.20 yuan.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments